Gilead Sciences | GJELD



Debt Endring Dato
AbbVie USD 67.14B 3.94B 2024-12
Agios Pharmaceuticals USD 0 0 2024-12
ALKERMES USD 0 366M 2024-12
Alnylam Pharmaceuticals USD 1.02B 967K 2024-12
Amgen USD 60.1B 299M 2024-12
Biogen USD 6.3B 1.9M 2024-12
BioMarin Pharmaceutical USD 596.24M 1.61M 2024-12
Bristol-Myers Squibb USD 49.65B 103M 2024-12
Eli Lilly USD 33.64B 2.52B 2024-12
Gilead Sciences USD 26.71B 3.46B 2024-12
GlaxoSmithKline GBP 16.99B 927M 2024-12
Glaxosmithkline GBP 16.99B 927M 2024-12
Incyte USD 37.96M 5.81M 2024-12
J&J USD 36.63B 883M 2024-12
Merck USD 37.11B 1.02B 2024-12
Moderna USD 62M 593M 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 31.26B 828M 2024-12
Pfizer USD 64.35B 3.35B 2024-12
PTC Therapeutics USD 2.39B 389K 2024-12
Regeneron Pharmaceuticals USD 2.7B 400K 2024-12
Sanofi 23.75B 5.33B 2024-06
Sarepta Therapeutics USD 1.14B 90.44M 2024-12
United Therapeutics USD 300M 100M 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Gilead Sciences GJELD - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.